Cell Source, Inc. Files 2023 Annual Report

TL;DR

Cell Source (CLCS) filed its 2023 10-K. All systems go.

AI Summary

Cell Source, Inc. filed its 10-K for the fiscal year ending December 31, 2023. The company, formerly known as TICKET TO SEE, INC., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 57 West 57th Street, Suite 400, New York, NY 10019.

Why It Matters

This filing provides a comprehensive overview of Cell Source, Inc.'s financial performance and business operations for the past fiscal year, crucial for investors and stakeholders to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — The provided text is a standard 10-K filing header and does not contain specific financial performance data or forward-looking statements that would indicate a high risk.

Key Players & Entities

• Cell Source, Inc. (company) — Filer of the 10-K
• TICKET TO SEE, INC. (company) — Former name of Cell Source, Inc.
• 20231231 (date) — Fiscal year end date
• 20240624 (date) — Filing date
• 57 WEST 57TH STREET SUITE 400 NEW YORK NY 10019 (address) — Business and mailing address

FAQ

Key Financial Figures

• $0.001 — Section 12(g) of the Act: Common stock, $0.001 par value Indicate by check mark whet
• $100 million — g Company As a company with less than $100 million in revenue during our last fiscal year
• $250 m — al year and a public float of less than $250 million, we qualify as a "smaller reporti
• $500,000 — involves high cost (can reach close to $500,000 per infusion) and significant safety ri
• $48 billion — od cancer therapeutics was estimated at $48 billion in 2022 and is projected to increase in
• $98 billion — projected to increase in size to reach $98 billion by 2030 according to DataBridgeGlobal B
• $480,000 — of the infusion in some cases exceeding $480,000 in the US. The broader hope for CAR-T c

Filing Documents

• form10-k.htm (10-K) — 2606KB
• ex10-69.htm (EX-10.69) — 40KB
• ex10-70.htm (EX-10.70) — 40KB
• ex10-71.htm (EX-10.71) — 39KB
• ex10-72.htm (EX-10.72) — 38KB
• ex10-73.htm (EX-10.73) — 40KB
• ex10-74.htm (EX-10.74) — 40KB
• ex31-1.htm (EX-31.1) — 11KB
• ex32-1.htm (EX-32.1) — 5KB
• form10-k_001.jpg (GRAPHIC) — 20KB
• form10-k_002.jpg (GRAPHIC) — 32KB
• form10-k_003.jpg (GRAPHIC) — 6KB
• form10-k_004.jpg (GRAPHIC) — 53KB
• form10-k_005.jpg (GRAPHIC) — 34KB
• form10-k_006.jpg (GRAPHIC) — 18KB
• form10-k_007.jpg (GRAPHIC) — 25KB
• form10-k_008.jpg (GRAPHIC) — 14KB
• 0001493152-24-024903.txt ( ) — 10457KB
• clcs-20231231.xsd (EX-101.SCH) — 60KB
• clcs-20231231_cal.xml (EX-101.CAL) — 63KB
• clcs-20231231_def.xml (EX-101.DEF) — 353KB
• clcs-20231231_lab.xml (EX-101.LAB) — 483KB
• clcs-20231231_pre.xml (EX-101.PRE) — 420KB
• form10-k_htm.xml (XML) — 1482KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 62 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 67 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data. 67 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. 67 Item 9A.

Controls and Procedures

Controls and Procedures. 68 Item 9B. Other Information. 68 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 68 PART III Item 10. Directors, Executive Officers and Corporate Governance. 69 Item 11.

Executive Compensation

Executive Compensation. 72 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 73 Item 13. Certain Relationships and Related Transactions, and Director Independence. 75 Item 14. Principal Accountant Fees and Services. 77 PART IV Item 15. Exhibits and Financial Statement Schedules. 78 Item 16. Form 10-K Summary. 81

Signatures

Signatures 82 CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements regarding, among other things, our anticipated financial and operating results. Forward-looking statements reflect our management's current assumptions, beliefs, and expectations. Words such as "anticipate," "believe," "estimate," "seek," "expect," "intend," "could," "plan," and similar expressions are intended to identify forward-looking statements. While we believe that the expectations reflected in our forward-looking statements are reasonable, we can give no assurance that such expectations will prove correct. Forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from the future results, performance, or achievements expressed in or implied by any forward-looking statement we make. Some of the relevant risks and uncertainties that could cause our actual performance to differ materially from the forward-looking statements contained in this report are discussed below under the heading "Risk Factors" and elsewhere in this Annual Report on Form 10-K. We caution investors that these discussions of important risks and uncertainties are not exclusive, and our business may be subject to other risks and uncertainties which are not detailed there. Investors are cautioned not to place undue reliance on our forward-looking statements. We make forward-looking statements as of the date on which this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission ("SEC"), and we assume no obligation to update the forward-looking statements after the date hereof whether as a result of new information or events, changed circumstances, or otherwise, except as required by law. i Summary of Principal Risk Factors Our business operations are subject to numerous risks, factors and uncertainties, including those outside our control that could cause our a

Business

Business We are a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary immune system management technology ("Cell Source technology") licensed from Yeda Research & Development Company Limited ("Yeda"), the commercial arm of the Weizmann Institute of Science ("Weizmann Institute") in Israel. The current focus of our Research and Development efforts is at the University of Texas MD Anderson Cancer Center ("MD Anderson") in Houston, Texas. This technology addresses one of the most fundamental challenges within human immunology: how to tune the immune response such that it tolerates selected desirable foreign cells, but continues to attack all other (undesirable) targets. In simpler terms, a number of potentially life-saving treatments have limited effectiveness today because the patient's immune system rejects them. For example, while HSCT – hematopoietic stem cell transplantation (e.g. bone marrow transplantation) has become a preferred therapeutic approach for treating blood cell cancer, most patients do not have a matched family donor. Although matched unrelated donors and cord blood can each provide an option for such patients, haploidentical stem cell transplants (sourced from partially mismatched family members) are rapidly gaining favor as a treatment of choice. This is still a risky and difficult procedure primarily due to potential conflicts between host and donor immune systems and as well as viral infections that often follow even successful HSCT while the compromised new immune system works to reconstitute itself by using the transplanted stem cells. Today, rejection is partially overcome using aggressive immune suppression treatments that leave the patient exposed to many dangers by compromising their immune system. The unique advantage of Cell Source technology lies in the ability to induce sustained tolerance of transplanted cells (or organs) by the recipient's immune system i

View Full Filing

View this 10-K filing on SEC EDGAR